How do I transfer my HER2-Low Breast Cancer care to another hospital

Transferring Your HER2-Low Breast Cancer Care to Another Hospital

I understand you're considering moving your care—this is an important decision for HER2-low breast cancer patients, especially given recent treatment advances. Let me walk you through the practical steps and what you should know.

Why This Matters for HER2-Low Breast Cancer

HER2-low breast cancer is a relatively newer classification that's opening up important treatment options. According to recent clinical guidance, trastuzumab deruxtecan (Enhertu) has shown significant benefits for HER2-low patients, with overall survival of 24 months compared to 17 months for chemotherapy alone. Not all hospitals may be equally experienced with these newer targeted approaches, so finding a center with expertise in HER2-low disease can be valuable.

Step-by-Step Transfer Process

1. **Request Your Complete [ID removed]

• Contact your current hospital's [ID removed] department
• Request: pathology reports, imaging scans (with images, not just reports), lab results, treatment summaries, and genetic testing results
• Ask specifically for your HER2 testing details (IHC score, FISH results, or protein expression levels if available)
• Pro tip: Request "underlying data" that informed your results, not just summaries—this gives your new team complete information

2. Choose Your New Hospital

Consider centers with:

• Breast cancer expertise in HER2-low disease specifically
• Multidisciplinary teams (oncologists, surgeons, radiologists working together)
• Access to clinical trials for newer HER2-targeted therapies
• Molecular tumor boards that review complex cases

According to cancer care experts, major academic centers like MD Anderson, Sloan Kettering, Johns Hopkins, Mount Sinai, Fred Hutchinson, and UCSF typically have robust breast cancer programs with access to newer treatment options and trials.

3. Schedule a Consultation

• Call the new hospital's breast cancer program directly
• Request an appointment with a medical oncologist experienced in HER2-low breast cancer
• Mention you're transferring care and have records to share
• Ask if they can do a second opinion review before your first visit

4. Prepare for Your First Appointment

Bring or have sent:

• All pathology slides (not just reports)
• Imaging studies on CD or via secure transfer
• List of all treatments received with dates
• Current medications and side effects you've experienced
• Questions about HER2-low specific treatment options

Important Considerations for Your Situation

Timing matters: If you're between treatment lines or early in your treatment journey, transferring is often smoother than mid-treatment. However, don't delay if you feel your current care isn't optimal.

Insurance coordination: Contact your insurance company before transferring to understand:

• Whether the new hospital is in-network
• Prior authorization requirements for treatments
• Coverage for newer drugs like Enhertu

Communication between doctors: Your new oncologist will likely contact your previous team to understand your complete treatment history, especially if you've had prior therapies. This helps them understand what you've already tried and how your cancer responded.

Questions to Ask Your New Care Team

1. "What is your experience treating HER2-low breast cancer specifically?"
2. "Do you have access to Enhertu (trastuzumab deruxtecan) and other HER2-targeted therapies?"
3. "Are there clinical trials for HER2-low breast cancer that I might be eligible for?"
4. "Will you do additional biomarker testing, such as hormone receptor status confirmation or other molecular profiling?"
5. "How will you coordinate my care if I need surgery, radiation, or other specialists?"

What the Experts Say

According to cancer care navigation experts, multidisciplinary team review is especially important for breast cancer patients because treatment decisions benefit from input from medical oncologists, surgical oncologists, radiation oncologists, and pathologists working together. This is particularly true for HER2-low disease, where the treatment landscape is evolving rapidly.

One important note: Some institutions may be more conservative about newer treatments, while others actively incorporate emerging therapies. If you're interested in cutting-edge HER2-low approaches, specifically ask about their willingness to use newer agents and their experience with them.

Red Flags to Avoid

• Hospitals that seem unfamiliar with HER2-low as a distinct category
• Centers that can't explain why they would or wouldn't recommend Enhertu for your specific situation
• Lack of multidisciplinary team involvement in treatment planning
• Inability to access your imaging studies or pathology slides

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Sources: NCCN Breast Cancer Guidelines, ASCO Clinical Practice Guidelines, American Cancer Society recommendations, and Cancer Patient Lab expert discussions on multidisciplinary cancer care coordination.